NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
March 16 2022 - 4:15PM
Business Wire
Conference Call and Webcast to be Held at 8:00
A.M. EDT/2:00 P.M CET on March 31, 2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the
‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a
late-stage clinical biotechnology company pioneering physics-based
approaches to expand treatment possibilities for patients with
cancer, today announces that it will report its financial results
for full-year ending December 31, 2021, on Wednesday, March 30,
2022, after the close of the US market.
The announcement will be followed by a conference call and live
audio webcast on Thursday, March 31, 2022, at 8:00 AM EDT / 2:00 PM
CET, prior to the open of the US market. During the call, Laurent
Levy, chief executive officer, and Bart Van Rhijn, chief financial
officer, will briefly review the Company’s year-end results and an
update on business activities before taking questions from analysts
and investors. Investors are invited to email their questions in
advance to investors@nanobiotix.com.
Details for the call are as follows:
Dial-In Information:
Live (US/Canada): +16467413167
Live France: +33170700781
Live (international): +44 (0) 2071 928338
Conference ID: 8169783
A live webcast of the call may be accessed by visiting the
investors section of the company's website at www.nanobiotix.com. A
replay of the webcast will be available shortly after the
conclusion of the call and will be archived on the company's
website.
***
About NBTXR3 NBTXR3 is a novel, potentially
first-in-class oncology product, composed of functionalized hafnium
oxide nanoparticles that is administered via one-time intratumoral
injection and activated by radiotherapy. The product candidate’s
physics-based mechanism of action (MoA) is designed to induce
significant tumor cell death in the injected tumor when activated
by radiotherapy, subsequently triggering adaptive immune response
and long-term anti-cancer memory. Given the MoA, Nanobiotix
believes that NBTXR3 could be scalable across any solid tumor that
can be treated with radiotherapy and across any therapeutic
combination, particularly, with immune checkpoint inhibitors.
NBTXR3 is being evaluated in locally advanced head and neck
squamous cell carcinoma (HNSCC) as the primary development pathway.
The company-sponsored phase I dose escalation and dose expansion
study has produced favorable safety data and early signs of
efficacy. In February 2020, the United States Food and Drug
Administration granted regulatory Fast Track designation for the
investigation of NBTXR3 activated by radiation therapy, with or
without cetuximab, for the treatment of patients with locally
advanced HNSCC who are not eligible for platinum-based
chemotherapy.
Nanobiotix has also prioritized an Immuno-Oncology development
program—beginning with a Company sponsored phase I clinical study,
evaluating NBTXR3 activated by radiotherapy in combination with
anti-PD-1 checkpoint inhibitors for patients with locoregional
recurrent or recurrent/metastatic HNSCC and for patients with lung
or liver metastases from any primary cancer eligible for anti-PD-1
therapy, either naïve or resistant to prior PD-1 (either primary or
secondary as per SITC criteria).
Given the Company’s focus areas, and balanced against the
scalable potential of NBTXR3, Nanobiotix has engaged in strategic
collaborations to expand development of the product candidate in
parallel with its priority development pathways. Pursuant to this
strategy, in 2019 Nanobiotix entered into a broad, comprehensive
clinical research collaboration with The University of Texas MD
Anderson Cancer Center to sponsor several phase I and phase II
studies to evaluate NBTXR3 across tumor types and therapeutic
combinations. In 2021, the Company entered into an additional
strategic collaboration agreement with LianBio to support its
global phase III study in Asia along with four future
registrational studies.
About NANOBIOTIX Nanobiotix is a late-stage clinical
biotechnology company pioneering disruptive, physics-based
therapeutic approaches to revolutionize treatment outcomes for
millions of patients; supported by people committed to making a
difference for humanity. The company’s philosophy is rooted in the
concept of pushing past the boundaries of what is known to expand
possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, Germany and
Switzerland.
Nanobiotix has been listed on the regulated market of Euronext
in Paris since 2012 and on the Nasdaq Global Select Market in New
York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3 —which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220316005764/en/
Nanobiotix Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Investor Relations Department Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations FR – Ulysse Communication Pierre-Louis
Germain + 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com
US – Porter Novelli Dan Childs +1 (781) 888-5106
Dan.childs@porternovelli.com
Nanobiotix (EU:NANO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Dec 2023 to Dec 2024